Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.
We report a case of advanced prostate cancer in which an initial response to hormonal therapy with surgical castration and estramustine phosphate (EMP) was followed by disease progression, as shown by sequential elevations in serum prostate specific antigen (PSA) and prostate acid phosphatase (PAP) and the development of new symptoms, during maintenance endocrine and anti-cancer chemotherapy. Discontinuation of EMP resulted in sustained reductions in serum PSA and PAP levels and a sustained improvement in symptoms.
Nishiyama
T
T
Department of Urology, Koseiren Nagaoka Central General Hospital, Nagaoka, Japan.
Terunuma
M
M
D000135:Acid Phosphatase / Q000378:metabolism*; D000230:Adenocarcinoma / Q000737:chemistry* / Q000188:drug therapy; D014408:Biomarkers, Tumor / Q000032:analysis*; D001859:Bone Neoplasms / Q000556:secondary; D002369:Castration; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000201:enzymology*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000601:surgery
D014408:Biomarkers, Tumor; D004961:Estramustine; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen